

Isolated Limb Perfusion

Distinct Tourniquet and Tumor Necrosis Factor Effects on the Early Hemodynamic Response

Dimitri Christoforidis, MD; Pierre-Guy Chassot, MD; François Mosimann, MD; Danielle Lienard, MD; Flavia Brunstein, MD; Dritan Bejko, MD; Ferdy J. Lejeune, MD; René Chiolero, MD

Hypothesis: Recent evidence indicates that tumor response rates after isolated limb perfusion (ILP) are improved when tumor necrosis factor (TNF) is added to the locoregional perfusion of high doses of chemotherapy. Other factors, related to the patient or the ILP procedure, may interfere with the specific role of TNF in the early hemodynamic response after ILP with TNF and high-dose chemotherapy.

Design: Case-control study.

Setting: Tertiary care university hospital.

Patients: Thirty-eight patients with a locoregionally advanced tumor of a limb treated by ILP with TNF and high-dose chemotherapy (TNF group) were compared with 31 similar patients treated by ILP with high-dose chemotherapy alone (non-TNF group).

Interventions: Swan-Ganz catheter hemodynamic recordings, patients' treatment data collection, and TNF and interleukin 6 plasma level measurements at regular intervals during the first 36 hours following ILP.

Main Outcome Measures: Hemodynamic profile and total fluid and catecholamine administration.

Results: In the TNF group, significant changes were ob-

served ($P < .006$): the mean arterial pressure and the systemic vascular resistance index decreased, and the temperature, heart rate, and cardiac index increased. These hemodynamic alterations started when the ILP tourniquet was released (ie, when or shortly after the systemic TNF levels were the highest). The minimal mean arterial pressure, the minimal systemic vascular resistance index, the maximal cardiac index, the intensive care unit stay, and the interleukin 6 maximal systemic levels were significantly ($P < .001$ for all) correlated to the \log_{10} of the systemic TNF level. In the non-TNF group, only a brief decrease in the blood pressure following tourniquet release and an increase in the temperature and in the heart rate were statistically significant ($P < .006$). Despite significantly more fluid and catecholamine administration in the TNF group, the mean arterial pressure and the systemic vascular resistance index were significantly ($P < .001$) lower than in the non-TNF group.

Conclusions: Release of the tourniquet induces a blood pressure decrease that lasts less than 1 hour in the absence of TNF and that is distinct from the septic shock-like hemodynamic profile following TNF administration. The systemic TNF levels are correlated to this hemodynamic response, which can be observed even at low TNF levels.

Arch Surg. 2003;138:17-25

From the Departments of General Surgery (Drs Christoforidis and Mosimann) and Anesthesiology (Dr Chassot), the Centre Pluridisciplinaire d'Oncologie (Drs Lienard and Lejeune), and the Intensive Care Unit of Surgery (Dr Chiolero), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; the Tumours Division, Plastic Surgery Department, Hospital São Paulo, São Paulo, Brazil (Dr Brunstein); and the Medical Oncology Unit, Catholic University of Louvain, Brussels, Belgium (Dr Bejko).

TUMOR NECROSIS factor (TNF) is a trimeric cytokine secreted by several cell types, including macrophages. It was identified in 1975 as the factor causing hemorrhagic necrosis of subcutaneous tumors in mice injected with endotoxin.¹ After human TNF recombination, the enthusiastically expected phase I trials of systemic administration turned out to be disappointing. Practically no antitumoral effect was observed, because the maximal tolerated dose was limited to insufficient levels by significant systemic toxicity, mainly fever, chills, malaise, anorexia, thrombocytopenia, and hypotension.²⁻⁵ Pessimism increased further because in the

same years TNF was shown to play a major role in the inflammatory cascade leading to septic shock.

Isolated limb perfusion (ILP) is a locoregional cancer treatment that allows high doses of antitumoral drugs to be perfused through the vascular bed of a limb while avoiding toxic systemic concentrations. It was first described in 1958,⁶ but gained wide acceptance only after Lienard et al⁷ reported 90% complete remission rates for advanced malignant melanoma and soft tissue sarcoma following hyperthermic ILP with high doses of melphalan combined with TNF and interferon gamma-1b. This significant antitumoral effect is caused by destruction of the

Table 1. Patients' Clinical Characteristics*

Characteristic	TNF Group (n = 38)	Non-TNF Group (n = 31)
Treatment		
Melphalan		
Alone	0	28
Plus TNF	11	0
Plus TNF and interferon gamma-1b	27	0
Fotemustine	0	3
Male-female ratio	24:14	18:13
Age, mean (range), y	54.6 (19-79)	58.7 (30-87)
Indication for ILP		
Malignant melanoma	30	29
Soft tissue sarcoma	5	1
Squamous cell carcinoma	2	0
Merkel cell carcinoma	0	1
PNET	1	0
Limb affected		
Lower	30	29
Upper	8	2
ASA score ≥ 3	5	5
History of coronary disease, cardiac failure, or atrial fibrillation	6	3

Abbreviations: ASA, American Society of Anesthesiologists; ILP, isolated limb perfusion; PNET, peripheral neuroectodermal tumor; TNF, tumor necrosis factor.

*Data are given as number of patients in each group unless otherwise indicated. Patients in the TNF group were treated with ILP and high-dose chemotherapy, with TNF; and those in the non-TNF group, with ILP and high-dose chemotherapy, without TNF. The only significant difference between the 2 groups was in the number of patients with an upper limb affected ($P = .07$).

tumor at 2 levels: in addition to the cytotoxic effect of melphalan, TNF selectively induces apoptosis of endothelial cells of the tumor vessels, leading to the disruption of the tumor vasculature and to coagulative necrosis.⁸ However, leakage from the ILP circuit can lead to high levels of TNF in the systemic circulation. A septic shock-like syndrome with hypotension and low systemic vascular resistances after TNF administration and ILP has indeed been described,⁹⁻¹² although plasma TNF levels up to 10 000 times higher than those observed with lethal septic shock were not fatal. However, the hemodynamic response to TNF was variable and the role of TNF vs surgical and anesthesia variables was not determined. This prompted us to investigate the role of TNF in the early hemodynamic response to ILP. We collected retrospectively the data of 38 patients who underwent ILP with TNF and chemotherapy and compared them with those of 31 patients treated with ILP and chemotherapy only.

METHODS

PATIENTS

Between February 5, 1992, and September 7, 1994, 38 consecutive patients underwent hyperthermic ILP with TNF and melphalan, with or without interferon gamma-1b (TNF group). They were compared with 31 patients who underwent ILP without TNF from May 26, 1993, to October 17, 2000, with either melphalan (n=28) or fotemustine (n=3) (non-TNF group). All

patients were operated on at the Centre Hospitalier Universitaire Vaudois, by the same team of surgeons (F.J.L., F.M., and D.L.) and anesthetists (P.-G.C.), except 4 patients in the non-TNF group who were treated at the Hospital São Paulo by one of us (F.B.). The indications for ILP were malignant melanoma, soft tissue sarcoma, squamous cell carcinoma, Merkel cell carcinoma, and peripheral neuroectodermal tumor, always at a locoregionally advanced stage. The patients' main clinical characteristics are shown in **Table 1**. All patients treated with TNF, melphalan, or fotemustine were included in phase 1 and 2 studies approved by the local ethics committee; most studies¹³⁻¹⁷ were published.

ISOLATED LIMB PERFUSION

The details of the technique have been published before.^{7,13} In brief, the major artery and vein of the diseased limb (iliac, femoral, or axillary) are clamped and cannulated. Isolation of the extracorporeal circuit is obtained by ligation of the collateral vessels and application of a tourniquet at the root of the limb. After ILP is started, the temperature of the limb is increased and maintained between 39°C and 40°C using a warming blanket and heated perfusions. When stable perfusion conditions are reached, leakage from the limb into the systemic circulation is assessed by the technetium Tc 99m albumin radiolabeled human serum method.^{18,19} When the leakage rate is nil or minimal, TNF is injected as a bolus into the circuit. Thirty minutes later, melphalan or fotemustine is added and circulates for another 60 minutes. The total drug perfusion time is, therefore, 90 minutes in the TNF group and 60 minutes in the non-TNF group. At the end of the perfusion, the limb is rinsed for at least 10 minutes with 4 to 5 L of a colloid solution before the tourniquet is released. The vein and then the artery are decannulated and repaired.

ANESTHESIA

The induction of anesthesia and the use of muscular relaxants were similar in both groups. In all the TNF group patients, anesthesia was maintained mainly by benzodiazepines and fentanyl citrate. Isoflurane was administered to only 12 (32%) of these patients to avoid hypotension; nitrous oxide was used in 7 (18%) of the patients. On the contrary, in the non-TNF group, isoflurane was used in 30 (97%) of the patients and nitrous oxide in 19 (61%) of the patients; only 1 (3%) of the patients received long-acting benzodiazepines ($P < .01$). Dopamine hydrochloride, 3 to 5 $\mu\text{g}/\text{kg}$ per minute, was administered prophylactically from the beginning to all but 1 of the patients in the TNF group. In the non-TNF group, intraoperative dopamine was given only as clinically indicated (to 9 [29%] of the 31 patients). Intravenous indomethacin was administered to the TNF group patients only (50 mg over 4 hours, followed by 200 mg over the next 20 hours), to decrease systemic inflammatory adverse effects.

DRUGS

The TNF group patients received this cytokine as a 4- or 3-mg bolus for a lower or an upper limb, respectively. For safety reasons (poor leakage control or hypotension), one patient received 2 mg initially and 1 mg 30 minutes later, instead of a single 4-mg bolus. A second patient received 1 mg initially and 1 mg 30 minutes later instead of the planned 4-mg bolus. Finally, a third patient received 2 mg initially and 1 mg 30 minutes later instead of a 3-mg bolus.

Twenty-seven patients in the TNF group also received 0.2 mg (or 1.5×10^6 U) of interferon gamma-1b subcutaneously for 2 days before ILP, and another dose was injected in the per-

fusion circuit at the beginning of the procedure. Melphalan (Alkeran; Glaxo Wellcome Inc, Uxbridge, England) was given 30 minutes after TNF as a bolus of 10 or 13 mg/L of lower or upper limb volume, respectively (range, 32-115 mg). Fotemustine (Muphoran; Servier, Nevelly-sur-Seine CEDEX, France) was administered as melphalan, at a dose of 25 mg/L of limb volume.

HEMODYNAMIC DATA

A 7F Swan-Ganz catheter (Baxter Healthcare Corp, Deerfield, Ill) was positioned after the induction of anesthesia in all the TNF group patients. The temperature, heart rate (HR), mean arterial pressure (MAP), central venous pressure (CVP), mean pulmonary arterial pressure, pulmonary capillary wedge pressure (PCWP), cardiac index (CI), and stroke volume index (SVI) were recorded at least once during 8 predetermined periods before, during, and after ILP. These periods were defined as follows: (1) during anesthesia, before ILP; (2) during ILP, before drug perfusion; (3) during ILP with drug perfusion, before tourniquet release; (4) after tourniquet release and up to 3 hours after drug perfusion; (5) 3 to 6 hours after the initiation of drug perfusion; (6) 6 to 12 hours after the initiation of drug perfusion; (7) 12 to 24 hours after the initiation of drug perfusion; and (8) 24 to 36 hours after the initiation of drug perfusion. Cardiac output was measured in triplicate by the thermodilution method, injecting 10 mL of 5% glucose at room temperature.²⁰ Whenever more than 1 measurement was performed during a given period, the arithmetic mean was calculated. The systemic vascular resistance index (SVRI) was calculated as follows:

$$SVRI = [(MAP - CVP) \times 80] / CI$$

The pulmonary vascular resistance index (PVRI) was calculated as follows:

$$PVRI = [(MAPP - PCWP) \times 80] / CI$$

In the non-TNF group, 12 patients had Swan-Ganz catheter measurements (December 2, 1998–October 17, 2000); only basic data (blood pressure, HR, and temperature) were recorded in the other 19 patients.

To define more precisely the tourniquet release effect, the HR and the systolic and diastolic pressures were recorded in all patients 10 minutes before and then 5, 30, and 60 minutes after the release. From these recordings, the MAP was calculated as follows:

$$MAP = \text{Diastolic Pressure} + [(\text{Systolic Pressure} - \text{Diastolic Pressure}) / 3]$$

CYTOKINE LEVELS

All TNF group patients underwent measurement of systemic levels of TNF and interleukin 6 (IL-6) during and up to 36 hours after the initiation of ILP. The TNF level was measured using the WEHI 164 clone 13 cell line.²¹ A standard curve was obtained using TNF from the same batch as that given to the patients. The lower limit of detection was 0.5 pg/mL.

The level of IL-6 was measured using IL-6–dependent mouse-mouse hybridoma cells (7TD1). Interleukin 6 concentrations were expressed in units per milliliter, with 1 U being the dose of IL-6 inducing a 50% proliferation.

STATISTICAL ANALYSES

Data were analyzed using a statistical software program (Statistical Product and Service Solutions, version 8.0; SPSS Inc, Chicago, Ill). Patients' characteristics (Table 1) and the percentage of patients treated with catecholamines (Table 2) from the TNF group and the non-TNF group were compared using the Pearson χ^2 test. Patients' treatment variables (Table 3) were compared between groups using the *t* test for comparison of means. Hemodynamic measurements are given as mean \pm 95% confi-

Table 2. Patients Treated With Catecholamines*

Catecholamine	TNF Group (n = 38)	Non-TNF Group (n = 31)	P Value
Dopamine hydrochloride†	37 (97)	11 (35)	<.001
Norepinephrine bitartrate‡	28 (74)	2 (6)	<.001
Dobutamine hydrochloride§	14 (37)	2 (6)	.01
Epinephrine	3 (8)	0	...

Abbreviation: TNF, tumor necrosis factor.

*Data are given as number (percentage) of patients unless otherwise indicated. The TNF group and the non-TNF group are described in the second footnote to Table 1.

†Those treated with 400 μ g/min or more included 11 (29%) of the patients in the TNF group and 3 (10%) of the patients in the non-TNF group.

‡Those treated with 10 μ g/min or more included 18 (47%) of the patients in the TNF group and 0 patients in the non-TNF group.

§Those treated with 300 μ g/min or more included 12 (32%) of the patients in the TNF group and 1 (3%) of the patients in the non-TNF group.

Table 3. Patient Treatment Variables*

Variable	TNF Group	Non-TNF Group	P Value
RBCs transfused intraoperatively, U	3.9 \pm 1.1	1.2 \pm 0.5	<.001
Postoperative hemoglobin level, g/dL	10.2 \pm 0.5	9.4 \pm 1.0	.11
Fluid balance, L			
At 24 h	8.5 \pm 1.4	5.7 \pm 0.7	.005
At 36 h	8.6 \pm 1.5	5.5 \pm 0.9	.002
Operation duration, min	314 \pm 14	277 \pm 20	.001
ICU stay, h	75.9 \pm 13.3	†	...
Tracheal intubation time, h	37.9 \pm 7.7	‡	...

Abbreviations: ICU, intensive care unit; RBC, red blood cell; TNF, tumor necrosis factor.

*Data are given as mean \pm 95% confidence interval. The TNF group and the non-TNF group are described in the second footnote to Table 1.

†Only 2 patients needed an ICU stay.

‡All patients were extubated in the operating room.

dence interval (Figures 1, 2, 3, and 4). A 1-way analysis of variance for repeated measurements was used to compare the values at different time points in a given patient group, with Tukey and Bonferroni corrections for 8 repeated measures (periods 1-8) or for 4 repeated measures (tourniquet recordings). To compare values between groups at a given time point, the 2-tailed *t* test was used. Correlations to TNF (Table 4) were calculated by linear regression analysis with logarithmic transformations when necessary to ensure a normal distribution.

RESULTS

HEMODYNAMIC DATA

The evolution of the mean temperature, HR, MAP, CVP, pulmonary arterial pressure, PCWP, CI, SVRI, SVI, and PVRI in the TNF group and the non-TNF group is presented in Figures 1 through 4.

The temperature differed significantly between the 2 groups 3 to 24 hours after ILP: fever was observed in the TNF group only 6 to 12 hours after ILP (maximum mean temperature, 38.1°C).

The mean HR in the TNF group patients increased to a maximum of 120 beats/min (166% of baseline) 3 to 6 hours post-ILP; it decreased thereafter, but tachycar-




Figure 1. Changes in temperature (A) and heart rate (B) during periods 1 through 8 (defined in the “Hemodynamic Data” subsection of the “Methods” section). Data are given as mean \pm 95% confidence interval. The TNF group indicates patients treated with isolated limb perfusion (ILP) and high-dose chemotherapy, with tumor necrosis factor (TNF); non-TNF group, patients treated with ILP and high-dose chemotherapy, without TNF; an asterisk between the curves, a significant ($P < .05$) difference between the TNF group and the non-TNF group; and an asterisk above or below the curves, a significant ($P < .006$) difference of the corresponding reading compared with baseline (period 1).




Figure 2. Changes in arterial pressure (A) and central venous pressure (B) during periods 1 through 8 (defined in the “Hemodynamic Data” subsection of the “Methods” section). Data are given as mean \pm 95% confidence interval. A description of the groups and an explanation of the abbreviations and symbols are given in the legend to Figure 1.

dia persisted for at least 36 hours. The non-TNF group also showed a significant, but milder, increase in the mean HR, reaching 89 beats/min (127% of baseline).




Figure 3. Changes in the cardiac index (A), the stroke volume index (B), and the systemic vascular resistance index (C) during periods 1 through 8 (defined in the “Hemodynamic Data” subsection of the “Methods” section). Data are given as mean \pm 95% confidence interval. A description of the groups and an explanation of the abbreviations and symbols are given in the legend to Figure 1.

The MAP was significantly higher during anesthesia (periods 1-4) in the TNF group ($P = .03$). This may be explained by the more frequent use of isoflurane in the non-TNF group and the prophylactic early intraoperative administration of dopamine in the TNF group patients.

In the TNF group, the MAP began to decrease after tourniquet release and reached a nadir of 72.4 mm Hg (79% of baseline) at 6 to 12 hours after ILP. It remained low for at least 36 hours (range of individual minimal recordings, 53-59 mm Hg). It was significantly ($P < .001$) lower in the TNF group than in the non-TNF group at 6 to 36 hours after ILP. In the non-TNF group, no significant ($P = .29$) variation of the MAP was noticed, as recorded and averaged during periods 1 to 8, although the MAP after tourniquet release during period 4 decreased from 87.2 ± 4.1 to 79.9 ± 3.9 mm Hg ($P = .60$).

The CVP in the TNF group was significantly higher during period 6 than during ILP (periods 2 and 3). This was not the case in the non-TNF group.

In the TNF group, the CI ($HR \times SVI$) increased significantly ($P < .001$) after tourniquet release, explained by an HR increase despite a decrease of the SVI. The highest recording was obtained 24 to 36 hours after ILP, because of a marked increase of the SVI. These changes did not oc-




Figure 4. Changes in the pulmonary arterial pressure (A), the pulmonary capillary wedge pressure (B), and the pulmonary vascular resistance index (C) during periods 1 through 8 (defined in the "Hemodynamic Data" subsection of the "Methods" section). Data are given as mean \pm 95% confidence interval. The TNF group indicates patients treated with isolated limb perfusion (ILP) and high-dose chemotherapy, with tumor necrosis factor (TNF); non-TNF group, patients treated with ILP and high-dose chemotherapy, without TNF; and an asterisk, the 95% confidence interval exceeds the graph scale.

cur in the non-TNF group, but the limited number of recordings does not allow firm conclusions to be drawn.

The SVRI decreased sharply (-31%) in the TNF group after tourniquet release ($P < .001$). Thereafter, the readings were also below normal and significantly ($P = .002$) lower than in the non-TNF group. The lowest figures were obtained 24 to 36 hours after ILP. In the non-TNF group, the SVRI tended to decrease (-16%) on tourniquet release ($P = .76$) and was variable thereafter. Again, the limited number of measurements does not allow definitive conclusions.

The mean pulmonary arterial pressure and the PCWP varied little and remained within the normal range. In the TNF group, they tended to decrease during perfusion and were slightly, but not significantly ($P = .13$), higher than baseline readings 24 to 36 hours after ILP. During ILP, the PCWP was slightly, but not significantly, higher in the non-TNF group. The PVRI in the TNF group did not vary significantly ($P = .15$) throughout the observation time.

The effects of tourniquet release on HR and MAP in the non-TNF group (at 10 minutes before and 5, 30, and 60 minutes after tourniquet release) are shown in **Figure 5**:

Table 4. Correlations to the Log₁₀ of the Peak Systemic TNF Level

Variable	<i>r</i>	<i>P</i> Value
Log of the IL-6 max	0.79	<.001
Stay at the ICU (in hours)	0.68	<.001
MAP		
Min ₃₋₈	0.59	<.001
Decrease*	0.38	.02
CI		
Max ₃₋₈	0.55	<.001
Increase†	0.38	.03
SVRI		
Min ₃₋₈	0.53	<.001
Decrease‡	0.28	.12
Log of total norepinephrine bitartrate given in 36 h	0.30	.14
Log of liters of positive fluid balance at 36 h	0.23	.17
Temperature max ₃₋₈
Heart rate max ₃₋₈

Abbreviations: CI, cardiac index; ICU, intensive care unit; IL-6, interleukin 6; MAP, mean arterial pressure; max, maximum; max₃₋₈, maximum during periods 3 through 8; min₃₋₈, minimum during periods 3 through 8; SVRI, systemic vascular resistance index (periods are defined in the "Hemodynamic Data" subsection of the "Methods" section); TNF, tumor necrosis factor.

*Calculated as follows: MAP during period 1 minus MAP min₃₋₈.

†Calculated as follows: CI max₃₋₈ minus CI during period 1.

‡Calculated as follows: SVRI during period 1 minus SVRI min₃₋₈.




Figure 5. Tourniquet effects on mean arterial pressure (MAP) and heart rate in the patients treated with isolated limb perfusion and high-dose chemotherapy, without tumor necrosis factor. Data are given as mean \pm 95% confidence interval. The asterisk indicates a significant difference ($P < .01$) between the corresponding reading and the -10-minute value.

the MAP decreased by 10% ($P = .27$) and by 13% ($P < .01$) at 5 and 30 minutes, respectively, returning to baseline at 60 minutes (-4%) ($P = .76$). In the TNF group, compared with the readings at 10 minutes before release, the MAP decreased by 8% ($P = .02$) and by 11% ($P < .01$) at 5 and 30 minutes, respectively. Conversely to the non-TNF group, it remained low at 60 minutes after tourniquet release (-12%) ($P < .001$). The HR did not vary significantly during this period in either group.

PATIENT TREATMENT

Fluid management and the administration of vasoactive drugs are described in Tables 2 and 3 and in **Figure 6**.




Figure 6. Percentage of patients requiring administration of norepinephrine bitartrate and dobutamine in those treated with isolated limb perfusion (ILP) and high-dose chemotherapy, with tumor necrosis factor (TNF) (TNF group), and in those treated with ILP and high-dose chemotherapy, without TNF (non-TNF group). Periods 1 through 8 are defined in the "Hemodynamic Data" subsection of the "Methods" section.




Figure 7. A, Median of the systemic levels of tumor necrosis factor (TNF) (measured in nanograms per milliliter) and interleukin 6 (IL-6) (measured in units per milliliter) over time. B, Percentage of patients having their peak level at this point for TNF and for IL-6.

Patients in the TNF group underwent transfusion of more units of red blood cells, had more positive fluid balances, and needed more vasopressive drug support than patients in the non-TNF group, who could always be readily extubated at the end of ILP and only rarely needed intensive care unit (ICU) treatment. All TNF group patients were admitted to the ICU to receive intensive treatment, including mechanical ventilation. All patients survived.

Although dopamine was administered to all but one of the TNF group patients prophylactically, norepinephrine bitartrate and dobutamine hydrochloride were given in both groups only if clinically indicated. (In the TNF group, 7 patients received dopamine

alone; 16 received dopamine and norepinephrine bitartrate; 1 received dopamine and dobutamine; 10 received dopamine, dobutamine, and norepinephrine bitartrate; and 3 received dopamine, dobutamine, norepinephrine bitartrate, and epinephrine.) Illustrating the occurrence of hemodynamic alterations necessitating treatment, the percentages of patients receiving these 2 catecholamines are shown in both groups in Figure 6. Within the TNF group, patients who attained a peak systemic TNF level of greater than 100 ng/mL ($n=13$) were treated on average with significantly more additional catecholamines, besides dopamine, than patients with a peak systemic TNF level of less than 100 ng/mL ($n=25$) ($P=.04$). In addition, the maximal and the total norepinephrine bitartrate doses administered in the greater than 100-ng/mL TNF group were also significantly higher than in the less than 100-ng/mL TNF group ($P<.001$ [2-tailed t test] and $P=.001$ [Mann-Whitney test], respectively).

TNF AND IL-6 PHARMACOKINETIC VARIABLES

Systemic levels of TNF and IL-6 were measured in all TNF group patients at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 18, 24, and 36 hours after the TNF bolus injection into the ILP circuit. Maximal systemic TNF levels ranged from 0.03 to 1728 ng/mL. Systemic TNF was detectable in 32 (84%) of the patients during ILP and in 37 (97%) of the patients 2 hours after the TNF injection (ie, shortly after tourniquet release). Ten hours after the TNF injection, fewer than 4 (11%) of the patients still had detectable systemic levels. **Figure 7** illustrates the median systemic TNF and IL-6 levels and the percentages of patients attaining their maximal levels at a given period. The IL-6 levels peaked on average 2.85 ± 0.45 hours after the highest TNF level.

CORRELATIONS WITH SYSTEMIC TNF LEVELS

The TNF peak systemic level ($r=0.98$, $P<.001$) is strongly correlated to the area under the curve of the TNF systemic level in time.²² Correlations between the \log_{10} of the peak TNF level and different hemodynamic variables, doses of norepinephrine bitartrate, fluid balance, duration of ICU stay, and IL-6 levels are shown in Table 4. Peak systemic concentrations of TNF correlated well with peak systemic concentrations of IL-6 and with the duration of ICU stay. There were decreases of individual MAP and SVRI values at all TNF plasma concentrations, from 0.03 up to 1728 ng/mL. The minimal readings of MAP and SVRI and the maximal readings of CI reached between TNF perfusion and 36 hours after ILP (periods 3-8) were well correlated to the \log_{10} of the peak TNF level (**Figure 8**). Weak correlations were found for the log of total norepinephrine bitartrate used and for the log of the number of liters of positive fluid balance at 36 hours.

COMMENT

Our study compared the hemodynamic profiles in 2 groups of patients treated with ILP, with or without TNF,

to define the specific role of TNF in the early hemodynamic response. We observed 2 distinct hemodynamic responses over time: a tourniquet release effect and a TNF-induced distributive shock.

The TNF group and the non-TNF group experienced an MAP decrease of approximately 10%, 5 and 30 minutes after tourniquet release. The CI significantly increased and the SVRI significantly decreased after tourniquet release (period 4) in the TNF group. In the non-TNF group, the CI also tended to increase and the SVRI to decrease, but not significantly. The previously mentioned changes normalized in the non-TNF group within an hour, while in the TNF group, they persisted for at least 36 hours. It follows, therefore, that tourniquet release induces immediate hemodynamic changes that are overridden by the effects of TNF.

In orthopedic surgery, a thigh tourniquet induces arterial hypertension,^{23,24} presumably by reduction of the vascular bed, by intravascular volume expansion due to exsanguination of the operated-on limb, and, most important, because of pain and ischemia.^{25,26} When the tourniquet is released, the systolic blood pressure decreases by 15% to 20%, back to the baseline readings or lower; this is related to a decrease of the vascular resistances by an increased total vascular cross-sectional area, reactive hyperemia, and circulation of ischemia-induced metabolites. In a study by Girardis et al,²⁷ the CI increased and the SVRI decreased in young male patients (mean±SD age, 25.7±6.8; range, 18-38 years) for the first 15 minutes following tourniquet release; these effects are blunted with increasing age.^{28,29} During ILP, the tourniquet does not induce ischemia, because this is prevented by the extracorporeal circulation. However, hyperthermia and the perfusion of high doses of cytotoxic drugs may produce vasoactive metabolites that may have the same effect as a tourniquet in orthopedic surgery.

Tumor necrosis factor induced hemodynamic changes that were not observed in the non-TNF group. Being retrospective and nonrandomized, we are aware that our study has limitations. The hemodynamic data were collected at different time points so that we had to define in retrospect the periods during which the recordings were averaged. In addition, the administration of catecholamines and fluids was as clinically indicated and did not obey precise predetermined criteria; this may have influenced the hemodynamic variables. The value of the statistical analysis performed within and between the 2 groups may, therefore, be debated. It can reasonably be assumed that the differences between the TNF group and the non-TNF group would probably have been even greater if no catecholamines had been perfused to the patients in the TNF group.

Despite aggressive fluid loading and vasoactive support, TNF group patients presented for at least 36 hours with tachycardia, hypotension, a high cardiac output, and low systemic resistances, thus mimicking septic shock.³⁰ No significant changes of the pulmonary artery pressure profile were observed.

This finding of a TNF-induced vasoplegia and loss of vascular tone fits with previous experimental data showing that TNF increases endothelial permeability³¹ and in-




Figure 8. Correlation of the log₁₀ of the peak systemic tumor necrosis factor (TNF) level to individual minimal mean arterial pressure (MAP) (A), minimal systemic vascular resistance index (SVRI) (B), and maximal cardiac index (CI) (C) recordings.

duces a vasodilation state with a depressed response to norepinephrine bitartrate^{32,33} that persists even after the cytokine is eliminated.³⁴ The mechanism of this TNF-induced vasoplegia is mainly nitric oxide (NO) dependent,^{35,36} although other endothelium-independent pathways have also been incriminated.³⁷ Tumor necrosis factor causes inducible NO synthase expression,³⁸⁻⁴⁰ so that NO can be produced for several days.^{41,42}

Our pharmacokinetic measurements suggest that, in the ILP setting, the presence of TNF in the systemic circulation results from 2 distinct mechanisms: one is leakage from the extracorporeal circuit, and the other is delivery of the cytokine into the systemic compartment when the tourniquet is released. This may happen despite a generous washout of the limb with colloid solutions for more than 10 minutes before the release. In fact, we documented a significant sequestration of radiolabeled albumin in the perfused limb after intensive washout (results not shown), strongly suggesting that TNF was retained in the tissue and released on revascularization. In our TNF group, the peak systemic levels ranged between 0.03 and 1728 ng/mL. The individual peak systemic TNF levels correlated well with the individual minimal recordings of MAP ($r=0.59$) and SVRI ($r=0.53$) and with the individual maximal recordings of CI ($r=0.55$). All but 3 patients in the TNF

group had an MAP reading below 75 mm Hg and an SVRI reading below $1600 \text{ dyne} \times \text{s} \times \text{m}^2/\text{cm}^5$ at least during one period after TNF perfusion (periods 3-8). The 3 patients who did not experience MAP and SVRI decreases below the norm had low TNF peak levels (0.48-7.36 ng/mL), but most patients with TNF peak levels in this range had an MAP below 75 mm Hg and an SVRI below $1600 \text{ dyne} \times \text{s} \times \text{m}^2/\text{cm}^5$ at least during one period after TNF perfusion (periods 3-8). In addition, patients with high systemic TNF levels ($>100 \text{ ng/mL}$) needed significantly more catecholamines and significantly higher norepinephrine bitartrate doses than patients with lower TNF levels, reflecting stronger hemodynamic changes in the former.

Casey et al,⁴³ in 97 patients with a sepsis syndrome, found detectable systemic TNF levels in 54% of the patients, with a median level of 0.026 ng/mL (range, 0-1.0 ng/mL). In another study⁴⁴ on patients with meningococcal disease, all patients who had a systemic level of TNF above 0.1 ng/mL died.

The TNF levels reported in this study are well above these values. This may explain why almost all TNF group patients experienced significant hemodynamic changes. A strong induction of inducible NO synthase by the high doses of TNF during ILP in the vascular bed of the treated limb and subsequent locoregional production of NO may also explain the systemic hemodynamic effects after ILP for as long as 36 hours.

Clinicians should be aware of the potential risks of ILP with TNF because even if leakage is controlled and the limb is rinsed, some TNF will still be released into the systemic circulation after tourniquet release. In addition, even low systemic TNF levels after ILP can induce a septic shock-like syndrome. All patients receiving TNF require, therefore, appropriate hemodynamic monitoring, aggressive fluid perfusion, and, if necessary, the administration of vasoactive amines to minimize the unavoidable, although often mild, vasoplegia. This is not the case for ILP without TNF administration.

In conclusion, our study demonstrates that the release of the tourniquet induces a specific decrease of the blood pressure during ILP with or without TNF administration. This effect is, however, short-lived in the absence of exogenous TNF. It is distinct from the septic shock-like hemodynamic profile observed after ILP with TNF administration, which may occur even at the lowest systemic TNF levels and which requires appropriate hemodynamic monitoring and support.

Accepted for publication September 7, 2002.

This study was presented in part at the 88th Annual Congress of the Swiss Society of Surgery, Luzern, Switzerland, June 7, 2001, and at the Second Beromun Expert Meeting, Barcelona, Spain, June 22, 2001.

We thank Boehringer Ingelheim, Ingelheim, Germany, for providing the recombinant human TNF and interferon gamma-1b; and J. Van Snick, PhD, Ludwig Institute for Cancer Research, Brussels, Belgium, for providing the 7TD1 cells.

Corresponding author and reprints: Dimitri Christoforidis, MD, Service de Chirurgie, Centre Hospitalier Uni-

versitaire Vaudois, CHUV BH 10, Bugnon 11, CH-1011 Lausanne, Switzerland (e-mail: dchristo@hospsvd.ch).

REFERENCES

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci U S A*. 1975;72:3666-3670.
2. Bartsch HH, Pfizenmaier K, Schroder M, Nagel GA. Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors [in German]. *Onkologie*. 1989;12:136-141.
3. Creaven PJ, Brenner DE, Cowens JW, et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. *Cancer Chemother Pharmacol*. 1989;23:186-191.
4. Zamkoff KW, Newman NB, Rudolph AR, Young J, Poiesz BJ. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. *J Biol Response Mod*. 1989;8:539-552.
5. Wiedenmann B, Reichardt P, Rath U, et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. *J Cancer Res Clin Oncol*. 1989;115:189-192.
6. Crech OJ. Chemotherapy of cancer: regional perfusion using an extracorporeal circuit. *Ann Surg*. 1958;148:616-632.
7. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *J Clin Oncol*. 1992;10:52-60.
8. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin $\alpha v \beta 3$ in the disruption of the tumor vasculature induced by TNF and IFN- γ . *Nat Med*. 1998;4:408-414.
9. Eggimann P, Chioloro R, Chassot PG, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. *Chest*. 1995;107:1074-1082.
10. Fawcett WJ, Hill S, Sheldon J, et al. Hemodynamic changes and circulating recombinant tumor necrosis factor- α concentrations in a patient undergoing isolated limb perfusion. *Crit Care Med*. 1993;21:796-800.
11. Villani F, Galimberti M, Mazzola G, et al. Cardiac and pulmonary effects of alpha tumor necrosis factor administered by isolation perfusion. *Tumori*. 1995;81:197-200.
12. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)- α concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF- α , interferon- γ , and melphalan. *Crit Care Med*. 1996;24:765-770.
13. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. *Ann Surg*. 1996;224:756-765.
14. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor- α in combination with interferon- γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. *J Clin Oncol*. 1996;14:2653-2665.
15. Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumor necrosis factor- α (TNF- α), interferon- γ (IFN- γ) and melphalan for melanoma stage III: results of a multi-centre pilot study. *Melanoma Res*. 1994;4(suppl 1):21-26.
16. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumor necrosis factor- α and melphalan with or without interferon- γ for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. *Melanoma Res*. 1999;9:491-502.
17. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNF α and melphalan for non-resectable soft tissue sarcoma of the extremities. *Eur J Surg Oncol*. 2000;26:669-678.
18. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. *Region Cancer Treat*. 1992;4:301-304.
19. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. *Br J Surg*. 1993;80:1124-1126.
20. Ganz W, Donoso R, Marcus HS, Forrester JS, Swan HJ. A new technique for measurement of cardiac output by thermodilution in man. *Am J Cardiol*. 1971;27:392-396.
21. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J Immunol Methods*. 1986;95:99-105.
22. Gerain J, Lienard D, Pampallona S, et al. Systemic release of soluble TNF recep-

- tors after high-dose TNF in isolated limb perfusion. *Cytokine*. 1997;9:1034-1042.
23. Valli H, Rosenberg PH, Kytta J, Nurminen M. Arterial hypertension associated with the use of a tourniquet with either general or regional anaesthesia. *Acta Anaesthesiol Scand*. 1987;31:279-283.
 24. Kaufman RD, Walts LF. Tourniquet-induced hypertension. *Br J Anaesth*. 1982; 54:333-336.
 25. Crews JC, Cahall M, Behbehani MM. The neurophysiologic mechanisms of tourniquet pain: the activity of neurons in the rostroventral medulla in the rat. *Anesthesiology*. 1994;81:730-736.
 26. Estebe JP, Malledant Y. Pneumatic tourniquets in orthopedics [in French]. *Ann Fr Anesth Reanim*. 1996;15:162-178.
 27. Girardis M, Milesi S, Donato S, et al. The hemodynamic and metabolic effects of tourniquet application during knee surgery. *Anesth Analg*. 2000;91:727-731.
 28. Modig J, Kolstad K, Wigren A. Systemic reactions to tourniquet ischaemia. *Acta Anaesthesiol Scand*. 1978;22:609-614.
 29. Parmet JL, Horrow JC, Berman AT, Miller F, Pharo G, Collins L. The incidence of large venous emboli during total knee arthroplasty without pneumatic tourniquet use. *Anesth Analg*. 1998;87:439-444.
 30. Thijs LG, Schneider AJ, Groeneveld AB. The haemodynamics of septic shock. *Intensive Care Med*. 1990;16(suppl 3):S182-S186.
 31. Jahr J, Grande PO. In vivo effects of tumor necrosis factor- α on capillary permeability and vascular tone in a skeletal muscle. *Acta Anaesthesiol Scand*. 1996; 40:256-261.
 32. Takahashi K, Ando K, Ono A, Shimosawa T, Ogata E, Fujita T. Tumor necrosis factor- α induces vascular hyporesponsiveness in Sprague-Dawley rats. *Life Sci*. 1992;50:1437-1444.
 33. Hollenberg SM, Cunnion RE, Parrillo JE. The effect of tumor necrosis factor on vascular smooth muscle: in vitro studies using rat aortic rings. *Chest*. 1991;100: 1133-1137.
 34. Naziri W, Joshua IG. Role of tumor necrosis factor- α in small intestinal microcirculation. *Am Surg*. 1998;64:203-210.
 35. Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. *Proc Natl Acad Sci U S A*. 1990;87:3629-3632.
 36. Baudry N, Vicaut E. Role of nitric oxide in effects of tumor necrosis factor- α on microcirculation in rat. *J Appl Physiol*. 1993;75:2392-2399.
 37. Johns DG, Webb RC. TNF- α -induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling. *Am J Physiol*. 1998; 275(pt 2):H1592-H1598.
 38. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon- γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. *Eur J Immunol*. 1988;18:1587-1592.
 39. Thiernemann C, Wu CC, Szabo C, Perretti M, Vane JR. Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. *Br J Pharmacol*. 1993;110:177-182.
 40. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. *Cell*. 1994; 78:915-918.
 41. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. *J Biol Chem*. 1994; 269:13725-13728.
 42. Magazine HI. Detection of endothelial cell-derived nitric oxide: current trends and future directions. *Adv Neuroimmunol*. 1995;5:479-490.
 43. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. *Ann Intern Med*. 1993;119:771-778.
 44. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. *Lancet*. 1987; 1:355-357.

IN OTHER AMA JOURNALS

ARCHIVES OF INTERNAL MEDICINE

Low- and High-Density Lipoprotein Cholesterol and Ischemic Cerebrovascular Disease: The Bezafibrate Infarction Prevention Registry

Nira Koren-Morag, PhD; David Tanne, MD; Eran Graff, PhD; Uri Goldbourt, PhD; for the Bezafibrate Infarction Prevention Study Group

Background: Despite increasing evidence that β -hydroxy- β -methylglutaryl coenzyme A reductase inhibitors reduce the incidence of stroke in patients with coronary heart disease (CHD), the associations between blood lipid levels and cerebrovascular disease (CVD) are not clear.

Objective: To evaluate whether blood cholesterol level and its fractions are risk factors for stroke in a large group of patients with CHD.

Methods: We followed up 11 177 patients with documented CHD who were screened for but not included in the Bezafibrate Infarction Prevention study, a secondary prevention randomized clinical trial of lipid modification, and had no history of stroke for subsequent CVD. During a 6- to 8-year follow-up period, 941 patients were identified as having nonhemorrhagic CVD, of whom 487 had verified ischemic stroke or transient ischemic attack (TIA).

Results: Increases in age-adjusted rates of both nonhemorrhagic CVD and verified ischemic stroke or TIA were identified with increasing cholesterol and low-density lipoprotein cholesterol levels, decreasing high-density lipoprotein cholesterol levels, and decreasing percentage of total serum cholesterol contained in the HDL moiety. In logistic regression models, adjusting for clinical covariates, the following odds ratios (95% confidence intervals) were identified for lipid values in the upper vs lower tertile for the end point of nonhemorrhagic CVD: total cholesterol, 1.43 (1.20-1.70); low-density lipoprotein cholesterol, 1.52 (1.27-1.81), high-density lipoprotein cholesterol, 0.84 (0.70-1.00); and percentage of serum cholesterol contained in HDL, 0.69 (0.58-0.83). Similar trends appeared for the end point of verified ischemic stroke or TIA.

Conclusion: These findings clearly support the role of total cholesterol and its fractions in prediction of ischemic CVD among patients with established CHD. (2002;162:993-999)

Corresponding author and reprints: Uri Goldbourt, PhD, Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel (e-mail: Goldbu1@ccsg.tau.ac.il).